Syngene International (SYNGENE) Stock Overview
A contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for SYNGENE from our risk checks.
SYNGENE Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Syngene International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹650.10 |
| 52 Week High | ₹960.60 |
| 52 Week Low | ₹599.55 |
| Beta | 0.040 |
| 1 Month Change | 2.93% |
| 3 Month Change | -7.56% |
| 1 Year Change | -24.53% |
| 3 Year Change | 4.61% |
| 5 Year Change | 20.74% |
| Change since IPO | 318.68% |
Recent News & Updates
Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Sep 23
Syngene International Limited Just Recorded A 65% EPS Beat: Here's What Analysts Are Forecasting Next
Jul 26Recent updates
Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Sep 23Syngene International Limited Just Recorded A 65% EPS Beat: Here's What Analysts Are Forecasting Next
Jul 26Syngene International's (NSE:SYNGENE) Profits Appear To Have Quality Issues
Jul 06Syngene International (NSE:SYNGENE) Is Paying Out A Dividend Of ₹1.25
Jun 27Syngene International (NSE:SYNGENE) Is Paying Out A Dividend Of ₹1.25
Jun 13Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
May 28Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Feb 15We Think Syngene International (NSE:SYNGENE) Can Stay On Top Of Its Debt
Jan 24
Company's Biologics Expansion And Automation Drive Robust Revenue Growth Ahead
Early recovery in Discovery Services and biologics manufacturing could lead to significant revenue growth from new collaborations and operational facilities.Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Shareholder Returns
| SYNGENE | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -1.5% | 1.3% | 0.3% |
| 1Y | -24.5% | 3.9% | 0.7% |
Return vs Industry: SYNGENE underperformed the Indian Life Sciences industry which returned 3.6% over the past year.
Return vs Market: SYNGENE underperformed the Indian Market which returned 1.9% over the past year.
Price Volatility
| SYNGENE volatility | |
|---|---|
| SYNGENE Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.4% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: SYNGENE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SYNGENE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,533 | Peter James Bains | www.syngeneintl.com |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Syngene International Limited Fundamentals Summary
| SYNGENE fundamental statistics | |
|---|---|
| Market cap | ₹258.78b |
| Earnings (TTM) | ₹5.07b |
| Revenue (TTM) | ₹37.27b |
Is SYNGENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNGENE income statement (TTM) | |
|---|---|
| Revenue | ₹37.27b |
| Cost of Revenue | ₹11.86b |
| Gross Profit | ₹25.42b |
| Other Expenses | ₹20.35b |
| Earnings | ₹5.07b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 12.74 |
| Gross Margin | 68.19% |
| Net Profit Margin | 13.61% |
| Debt/Equity Ratio | 12.2% |
How did SYNGENE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 07:56 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syngene International Limited is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |